Baird Medical Investment Holdings Ltd
Baird Medical Investment Holdings is a healthcare company focused on thyroid-related diseases. It designs, develops, manufactures and sells proprietary microwave ablation medical devices, including therapeutic apparatus and single-use ablation needles, and also distributes other medical devices. Its products are used in hospitals to treat conditions including thyroid nodules and liver cancer. Baird Medical sells to hospitals through direct sales, deliverers and distributors, which also serve as customers in its distribution channel. Microwave ablation devices are the company’s main source of business. It also develops software for its apparatus and has a research and development pipeline that includes AI-integrated robotic systems. The company’s principal executive office is in Guangzhou, China.
No SEC Form 4 filings for $BDMD in the last 30 days.
See all $BDMD insider activity →Baird Medical (BDMD) partners with ALLIS MED to distribute its medical devices in South Korea, aiming to introduce microwave ablation technology. ALLIS MED will handle regulatory submissions and become the exclusive distributor. Baird Medical has expanded into multiple new markets in 2026 and submitted recent FDA and CE applications for its Irreversible Electroporation System.
Baird Medical (BDMD) announced its partner Alpmed filed FDA and EU applications for an IRE ablation system, with targets for 2027 clearance. BDMD shares rose 47.47% to $0.16 during regular trading but fell 33% in after-hours trading.
Baird Medical (BDMD) and Alpmed submitted FDA 510(k) and EU CE applications for an IRE system in Q4 2026, targeting 2027 approvals. The system, designed for soft tissue ablation, could expand Baird's portfolio beyond its core MWA technology. Baird leads global regulatory efforts and holds worldwide commercial rights.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning BDMD (Baird Medical Investment Holdings Ltd). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent BDMD coverage spans financial news, regulation and market movers.
The partnership expands Baird Medical's geographic footprint and could drive revenue growth from the Korean market.
Regulatory filing for a new ablation system triggers a volatile price reaction.
Regulatory filing could unlock a new product line, expanding revenue potential.
Compliance risk may drive share price lower as investors assess delisting probability.
The disclosed initial order and expanded China distribution could modestly improve near-term revenue visibility, but the article lacks duration and future commitment details.
AlphAI scores every news story that mentions BDMD with an AI model for sentiment and relevance, and aggregates insider trades from Baird Medical Investment Holdings Ltd's SEC EDGAR Form 4 filings. Figures refresh continuously.
Baird Medical (BDMD) partners with ALLIS MED to distribute its medical devices in South Korea, aiming to introduce microwave ablation technology. ALLIS MED will handle regulatory submissions and become the exclusive distributor. Baird Medical has expanded into multiple new markets in 2026 and submitted recent FDA and CE applications for its Irreversible Electroporation System.
Baird Medical (BDMD) announced its partner Alpmed filed FDA and EU applications for an IRE ablation system, with targets for 2027 clearance. BDMD shares rose 47.47% to $0.16 during regular trading but fell 33% in after-hours trading.
Baird Medical (BDMD) and Alpmed submitted FDA 510(k) and EU CE applications for an IRE system in Q4 2026, targeting 2027 approvals. The system, designed for soft tissue ablation, could expand Baird's portfolio beyond its core MWA technology. Baird leads global regulatory efforts and holds worldwide commercial rights.
Baird Medical (NASDAQ: BDMD) received a Nasdaq notice for failing to meet the $1.00 minimum bid price requirement. The company has 180 days to comply by maintaining a closing bid price of at least $1.00 for 10 consecutive days. If it fails, it may qualify for an additional 180-day grace period. Baird Medical is evaluating options to regain compliance.
Baird Medical (BDMD) signed an exclusive distribution deal with China Resources Medical Devices to expand its microwave ablation technology in 19 Chinese markets. The initial order is valued at approximately $900,000. The agreement aims to increase product adoption in underserved regions. Baird Medical is also expanding in the US and other international markets.
Baird Medical (BDMD) received regulatory approvals in Vietnam and preliminary approval in Egypt for its microwave ablation technology, expanding its market reach. The company has FDA clearance and registrations in several other countries. CEO Haimei Wu highlighted the importance of these approvals for global expansion.
Baird Medical Investment Holdings Ltd (BDMD) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Baird Medical Reports 25% Revenue Growth and Positive Net Income for Six Months Ended June 30, 2026 Revenue increase driven by significant growth in the United States and other strategic markets NEW YORK, September 3, 2026 (GLOBE NEWSWIRE) -- Baird Medical Investment
Baird Medical Investment Holdings (NASDAQ: BDMD) said it signed a strategic cooperation agreement with Alpmed, a China-based IRE technology company, to develop and commercialize next-generation irreversible electroporation ablation. The firms plan a U.S. FDA 510(k) submission by end-2026 and potential clearance in 2027 for a soft-tissue tumor device.
